Comment by nozzpackon Dec 02, 2021 8:52am
165 Views
Post# 34189145
RE:RE:RE:Isotrentoin Market in US had 17.8 % Growth 2021
RE:RE:RE:Isotrentoin Market in US had 17.8 % Growth 2021Now I understand the agreement.
Royalties on all three absorica products until 2024.
However, CPH will be able to issue a NDA fpr isotrention as of November 2022.
That implies that CPH can launch its own generic absorica any timw after that date.
This will enable CPH to replace the royalties on Absorica AG...current generic ).....in 2024 with its own generic and presumably licence that generic in its other teritories.
Based on Epuris sales in Canada, generic absorica should continue to have robust generic sales well into the future.
It is probably generic sales that resulted in near 18 % increase in isotrention in the first 9 months of 2021.
Going forward, CPH royalties on its Sun Absorica products in the US ( 3 ) will depend on how well Absorica LD and Absoirica GH can compensate for the decline in sales of Absorica.
According to SUN, combined sales were stable.